Patient: Page 23

PharmaVoice Team/PharmaVoice

Software as a Service: Gaining Traction

Many research firms have predicted that the worldwide economic recession is responsible for the global increase in the software-as-a-service (SaaS) market revenue. According to a recent Gartner report, SaaS is forecast to have a 17.7% compound annual growth rate through 2013 for the aggregate ent...
By PharmaVoice Team • March 23, 2010
PharmaVoice Team/PharmaVoice

Advertising In the Digital Age

The difficult economic environment of the past 18 months has forced many pharma companies to reexamine their shrinking advertising budgets and make best use of the resources that remain. Sandra Peterson, president of the Bayer Medical Care unit of Bayer HealthCare, notes that Bayer HealthCare rec...
By PharmaVoice Team • March 12, 2010
Explore the Trendline➔

Stock via Getty Images

Trendline

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff
PharmaVoice Team/PharmaVoice

Opportunities in Oncology Development

Advances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, acco...
By PharmaVoice Team • Jan. 28, 2010
PharmaVoice Team/PharmaVoice

The Patient Pipeline

CLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ...
By PharmaVoice Team • Jan. 18, 2010
PharmaVoice Team/PharmaVoice

Industry Heal Thyself

The right MEDICINE TREWHITT. More than a year ago, key members of PhRMA’s executive board identified that there was a need to revisit the guidelines and make some improvements to eliminate the periodic complaints and allegations about the practices of sales representatives and their relationships...
By PharmaVoice Team • Jan. 11, 2010
PharmaVoice Team/PharmaVoice

The Salesforce of the Future

Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

R&D Business Models

The Changing R&D Business Model Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge. harmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing tec...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

Emerging Markets Poised for Growth

Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the gl...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

CRM: Connecting the Dots...

CUSTOMER RELATIONSHIP MANAGEMENT BY TAREN GROM CRM requires a multilevel, enterprisewide view of customers — thereby demanding a strong customer data management business practice . A 5% increase in customer retention can lead to a 25% to 85% profit increase,depending on the industry. — HarvardBus...
By PharmaVoice Team • Nov. 4, 2009
PharmaVoice Team/PharmaVoice

E-learning: A Virtual Classroom

Pharmaceutical companies are jumping on board the etrain as a way to better manage their internal learning initiatives The THE CLICK MAY NEVER REPLACE THE NO. 2 PENCIL, but elearning is becoming the teacher’s pet in terms of reach, content flexibility, access, and alleviating outofoffice downtime...
By PharmaVoice Team • Nov. 2, 2009
PharmaVoice Team/PharmaVoice

Sales Reps — What's Up Doc?

The relationship between the pharmaceutical sales representative and the physician has undergone a dramatic shift in recent years. In the past, the sales representative provided value to the physician, had an established and meaningful rela tionship, engaged in an interactive dialog, and acted as...
By PharmaVoice Team • Nov. 2, 2009
PharmaVoice Team/PharmaVoice

Creating Opportunity From Diversity

bring messages about their products to diverse groups in a way that is culturally sensitive, that will garner longterm goodwill of the communities, and that address the most press ing health concerns facing various racial and ethnic groups. Developing diverse marketing promotions and programs whe...
By PharmaVoice Team • Nov. 2, 2009
PharmaVoice Team/PharmaVoice

Planting the Seeds of a Blockbuster

Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing a...
By PharmaVoice Team • Oct. 23, 2009
PharmaVoice Team/PharmaVoice

Coming Into Focus

The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according t...
By PharmaVoice Team • Oct. 23, 2009
PharmaVoice Team/PharmaVoice

Beyond the Genome — Proteomics

Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February...
By PharmaVoice Team • Oct. 23, 2009
PharmaVoice Team/PharmaVoice

The Knowledge Revolution

In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009
PharmaVoice Team/PharmaVoice

The Creative Challenge

BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009
PharmaVoice Team/PharmaVoice

Vanlev: Coming Soon

In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...
By PharmaVoice Team • Aug. 12, 2009
PharmaVoice Team/PharmaVoice

PharmaTrax

Consumer shifts demand changes in healthcare marketing In its latest report on market insights, Cheskin, a strategic market research and consulting company, defines three consumer trends that are driving the evolution of the healthcare and lifesci ences industry: consumer enlightenment and empowe...
By PharmaVoice Team • March 10, 2009
PharmaVoice Team/PharmaVoice

GLOBAL Development

BY DENISE MYSHKO Drug developers are looking to emerging markets and increasing their outsourcing efforts as ways to access expertise and reach. Pharmaceutical companies will continue to globalize their preclinical and clinical development activities to increase speed-to-market and expand their p...
By PharmaVoice Team • Feb. 26, 2009
PharmaVoice Team/PharmaVoice

Buying Big GLOBAL

How M&A Impacts the Pharma Market As patent expirations and dwindling pipelines, along with an embattled economy, put a dent on pharma profits, acquisitions again become a necessity for large pharma companies seeking to maintain a healthy bottom line. With Pfizer’s purchase of Wyeth, among ot...
By PharmaVoice Team • Feb. 26, 2009
PharmaVoice Team/PharmaVoice

Venture Capital: Funding Challenges

VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded....
By PharmaVoice Team • Feb. 23, 2009
PharmaVoice Team/PharmaVoice

A Community Approach

As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronte...
By PharmaVoice Team • Feb. 23, 2009
PharmaVoice Team/PharmaVoice

Delivering on the Promise

BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict...
By PharmaVoice Team • Feb. 23, 2009
PharmaVoice Team/PharmaVoice

What's New

NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms a New Division to RESPOND TO PHARMACEUTICAL PUBLIC-RELATIONS CRISES Through a combination of in-depth therapeutic class analyses, events-driven Web research, and multi-stake holder image tracking and reputation assess...
By PharmaVoice Team • Feb. 22, 2009